Mixed Hepatocellular-cholangiocarcinoma
2 clinical trials · Condition
◉ Watch Mixed Hepatocellular-cholangiocarcinoma
| Record | Firm | Date |
|---|---|---|
| HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA) (NCT07105748) | Fudan University | 2025-08-15 |
| Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples (NCT02762721) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2016-06-06 |
Track Mixed Hepatocellular-cholangiocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.